Eating disorders unit 10


Published on

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Eating disorders unit 10

  1. 1. Types of Eating Anorexia Nervosa Bulimia Nervosa Binge Eating Disorder Not Otherwise Specified (NOS)
  2. 2. Anorexia Nervosa Warning Signs Dramatic weight loss Refusal to eat certain foods or food categories (e.g. no fats, no carbs) Consistent excuses to avoid situations involving food Excessive and rigid exercise routine Withdrawal from usual friends/relativesSource: National Eating Disorders Association Website
  3. 3. Anorexia Heart failure Kidney failure Low protein stores Digestive problems Electrolyte imbalance
  4. 4. Treatment for Anorexia1. Hospitalization  First consideration- return the patient’s nutritional state  Inpatient psychiatric treatment  Behavioral management  Individual psychotherapy  Family education and therapy  In some cases psychotropics
  5. 5. Treatment for Anorexia Pharmacotherapy  No identified medication that yields definitive improvement of core symptoms of anorexia  Some support for the use of cyproheptadine (Periactine)  Amitryptiline (Elavil)- also been reported to have some benefit  Other medications used with variable results  Clomipramine, primozide, chlorpromazine
  6. 6. Treatment for Anorexia Pharmacotherapy cont.  Trials with fluoxetine  Some weight gain  Serotonergic agents  May yield positive responses in the future  TCAs  In low-weight patients may result in  Hypotension, cardiac arrhythmia, dehydration  Upon return of normal nutritional state TCAs may be introduced.
  7. 7. Bulimia Nervosa DSM-IV-TR  Defined as binge eating combined with inappropriate ways of stopping weight gain
  8. 8. Bulimia Nervosa Warning Signs  Wrappers/containers indicating consumption of large amounts of food  Frequent trips to bathroom after meals  Signs of vomiting e.g. staining of teeth, calluses on hands  Excessive and rigid exercise routine  Withdrawal from usual friends/relativesSource: National Eating Disorders Association Website
  9. 9. Bulimia Nervosa According to the DSM-IV-TR  Bulimia nervosa is present when:  Episodes of binge eating occur relatively frequently  Twice a week or more for at least 3 month  Compensatory behaviors are practiced after binge eating to prevent weight gain:  Self-induce vomiting  Laxative abuse  Diuretics  Abuse of emetics  Severe dieting and strenuous exercise
  10. 10. Bulimia Nervosa According to the DSM-IV-TR  Bulimia nervosa is present when: Cont.  Wight is not severely lowered as in anorexia  The patient has morbid fear of fatness  A relentless drive for thinness  Disproportionate amount of self-evaluation depends on body shape and wight
  11. 11. Bulimia Nervosa Health Risks  Electrolyte imbalance  Laxative dependence  Dental problems  Stomach rupture  Menstruation irregularities
  12. 12. Treatment for BulimiaNervosa Pharmacotherapy  Antidepressants  Shown to be helpful  SSRIs (Fluoxetine 60 to 80 mg/day)  Reduce binge eating  Imipramine (Tofranil)  Desipramine (Norpramin)  Trazodone (Desyrel)  MAOIs have also been helpful  Carbamazepine (Tegretol) and lithium (Eskalith) – have not shown impressive results. Mostly used in bulimic patients with comorbid mood disorders such as bipolar I disorder.
  13. 13. Obesity Complex disease resulting from:  Genetic succeptibility  Increased availability of high-energy foods  Decreased physical activity
  14. 14. Obesity Accounts for:  25% of body weight in men  18% of body weight in women
  15. 15. Obesity Treatment  Obesity treatment is multifactorial  Treatment include  Diet  Exercise  Psychotherapy  Pharmacotherapy  In extreme cases:  Surgery
  16. 16. Obesity Pharmacotherapy –(See table 23.3-7 pg 746)  Drug treatment is effective because it suppresses appetite but tolerance may develop  Orlistat ( Xenical) approved by the FDA in 1999 for weight loss treatment (Currently sold OTC as “Alli”  Selective gastric and pancreatic lipase inhibitor  120 mg 3 times a day in combination with a low calorie diet and exercise
  17. 17. Obesity Orlistat  Prescription orlistat is used in overweight people who may also have:  high blood pressure  diabetes, high cholesterol  heart disease.  also used after weight-loss for maintenance  .Orlistat is a lipase inhibitors. It prevents some of the fat in foods eaten from being absorbed in the intestines. This unabsorbed fat is then removed from the body in the stool.
  18. 18. Obesity Sibutramine (Meridia)  β-phenylethylamine that inhibits reuptake of serotonin and epinephrine (and dopamine to a limited extent).  Approved by the FDA in 1997 for weight loss treatment and maintenance  Sibutramine is no longer available in the U.S. The manufacturer has decided to stop producing sibutramine based on information from a recent clinical study. In this study, people taking sibutramine had an increased risk of cardiovascular events such as heart attack and stroke
  19. 19. Obesity Orlistat- Side effects  oily spotting on underwear or on clothing  gas with oily spotting  urgent need to have a bowel movement  loose stools  oily or fatty stools  increased number of bowel movements  difficulty controlling bowel movements  pain or discomfort in the rectum (bottom)  stomach pain  irregular menstrual periods  headache  anxiety
  20. 20. Obesity Orlistat- Serious side effects- See doctor imnmediately hives rash itching difficulty breathing or swallowing severe or continuous stomach pain excessive tiredness or weakness nausea vomiting loss of appetite pain in the upper right part of the stomach yellowing of the skin or eyes dark-colored urine light-colored stools
  21. 21. Obesity Rimonabant  first in a new class of therapeutic agents called Cannabinoid-1 Receptor Blockers (CB1).  Shown to reduce body weight and reduce cv risk factors  Dose  20 mg causes significant weight loss  Reduction in waist circumference  FDAs Endocrine and Metabolic Drugs Advisory Committee recommended against the approval of rimonabant (known in the United States as Zimulti) due to concerns over similar serious side effects. Subsequently, the FDA did not approve rimonabant, and it has never been marketed in the United States.
  22. 22. Resources National Institutes of Health Publication No 02-4084. The Practical Guide: Identification, Evaluation, and Treatment of overweight and obesity in adults